Desvenlafaxine extended release: Phase III data

Data from a double-blind Phase III trial in 461 adult patients showed that 100 and 400 mg DVS-233 met the primary endpoint of reduction in HAM-D17 scores vs. placebo (p=0.0038 and p=0.0023, respective...